November 15, 2017
Circulogene’s Chen-Hsiung Yeh, Ph.D., CSO, was recently featured in a new article titled, Cell-Free DNA Drives Liquid Biopsy Testing published by Genetic Engineering & Biotechnology News.
“Chen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics, believes that what makes his company different is that the scientists try to make sure that they capture and target every single cfDNA as much as possible at the very first step. Circulogene launched cfDNA liquid biopsy clinical testing services in 2015. “For everybody in the liquid biopsy industry, isolating the DNA or RNA from the specimen is the universal common first step and the most overlooked step,” points out Dr. Yeh.”